PE - Boston Scientific reports positive results from EkoSonic Endovascular System trial

Boston Scientific (NYSE:BSX) announces positive results for the EkoSonic Endovascular System (EKOS system) at the Vascular InterVentional Advances (VIVA) meeting 2021. Data from the KNOCOUT PE registry – established to measure institutional adoption of a lower dose and lower-duration thrombolysis protocol, confirmed the safety and efficacy of EKOS system for the treatment of patients with intermediate-high and high-risk pulmonary embolism (PE). The international registry included data from of 489 patients. There were no intracerebral hemorrhagic (ICH) events, or brain bleeding events, with a low major bleeding rate of 2.5%, compared to the rate previously observed with systemic thrombolysis treatment. Results also demonstrated a 23% post-procedure reduction in the main indicator of heart strain from PE, measured as right ventricular to left ventricular diameter ratio (RV/LV). The ultrasound technology used by the EKOS system accelerates thrombolysis – the breakdown of the clot – minimizing the time it takes to treat a patient

For further details see:

Boston Scientific reports positive results from EkoSonic Endovascular System trial